WO2008096870A1 - アザ架橋環化合物 - Google Patents

アザ架橋環化合物 Download PDF

Info

Publication number
WO2008096870A1
WO2008096870A1 PCT/JP2008/052189 JP2008052189W WO2008096870A1 WO 2008096870 A1 WO2008096870 A1 WO 2008096870A1 JP 2008052189 W JP2008052189 W JP 2008052189W WO 2008096870 A1 WO2008096870 A1 WO 2008096870A1
Authority
WO
WIPO (PCT)
Prior art keywords
aza
bridged
muscarinic
receptor
antagonistic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052189
Other languages
English (en)
French (fr)
Inventor
Shinya Nagashima
Toru Kontani
Hiroshi Nagata
Yuji Matsushima
Hisao Hamaguchi
Tadatsura Koshika
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020097018755A priority Critical patent/KR20090107567A/ko
Priority to US12/524,758 priority patent/US8367696B2/en
Priority to AU2008212171A priority patent/AU2008212171A1/en
Priority to CA002678193A priority patent/CA2678193A1/en
Priority to MX2009008509A priority patent/MX2009008509A/es
Priority to JP2008557177A priority patent/JP5293192B2/ja
Priority to EP08711068A priority patent/EP2119716A4/en
Priority to BRPI0806972-7A2A priority patent/BRPI0806972A2/pt
Priority to CN2008800044089A priority patent/CN101605784B/zh
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of WO2008096870A1 publication Critical patent/WO2008096870A1/ja
Priority to IL200152A priority patent/IL200152A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

【課題】ムスカリンM3 受容体拮抗作用を有し、慢性閉塞性肺疾患(COPD)や喘息などの炎症性疾患の予防及び／または治療剤の有効成分として有用な化合物を提供する。【解決手段】本発明者らは、ムスカリンM3 受容体結合拮抗作用を有する化合物について検討し、下記式（１）のアザ架橋環化合物またはその塩がムスカリンM3 受容体結合拮抗作用を有することを確認し、本発明を完成した。本発明のアザ架橋環化合物はムスカリンM3 受容体結合拮抗作用を有し、慢性閉塞性肺疾患(COPD)や喘息等の炎症性疾患の予防及び／または治療剤として使用することができる。［R1 は、-H またはC1-6 アルキル；R2 は、式(a)，(b)，(c)および(d)からなる群より選択されるアザ架橋環であり；R3 は、チエニル、フェニル、ピリジル、ピラジニル、チアゾリル、またはピラゾリル；である］
PCT/JP2008/052189 2007-02-09 2008-02-08 アザ架橋環化合物 Ceased WO2008096870A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
BRPI0806972-7A2A BRPI0806972A2 (pt) 2007-02-09 2008-02-08 Composto cíclico contendo ponte azo
US12/524,758 US8367696B2 (en) 2007-02-09 2008-02-08 Aza-bridged-ring compound
AU2008212171A AU2008212171A1 (en) 2007-02-09 2008-02-08 Aza-bridged-ring compound
CA002678193A CA2678193A1 (en) 2007-02-09 2008-02-08 Aza-bridged-ring compound
MX2009008509A MX2009008509A (es) 2007-02-09 2008-02-08 Compuesto de anillo puenteado-aza.
KR1020097018755A KR20090107567A (ko) 2007-02-09 2008-02-08 아자 가교환 화합물
EP08711068A EP2119716A4 (en) 2007-02-09 2008-02-08 AZA BRIDGE CYCLE COMPOUND
JP2008557177A JP5293192B2 (ja) 2007-02-09 2008-02-08 アザ架橋環化合物
CN2008800044089A CN101605784B (zh) 2007-02-09 2008-02-08 氮杂桥环化合物
IL200152A IL200152A0 (en) 2007-02-09 2009-07-30 Aza-bridged-ring compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007030963 2007-02-09
JP2007-030963 2007-11-08

Publications (1)

Publication Number Publication Date
WO2008096870A1 true WO2008096870A1 (ja) 2008-08-14

Family

ID=39681769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052189 Ceased WO2008096870A1 (ja) 2007-02-09 2008-02-08 アザ架橋環化合物

Country Status (12)

Country Link
US (1) US8367696B2 (ja)
EP (1) EP2119716A4 (ja)
JP (1) JP5293192B2 (ja)
KR (1) KR20090107567A (ja)
CN (1) CN101605784B (ja)
AU (1) AU2008212171A1 (ja)
BR (1) BRPI0806972A2 (ja)
CA (1) CA2678193A1 (ja)
IL (1) IL200152A0 (ja)
MX (1) MX2009008509A (ja)
RU (1) RU2441868C2 (ja)
WO (1) WO2008096870A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2014051055A1 (ja) * 2012-09-28 2014-04-03 東レ株式会社 キヌクリジンウレア誘導体及びその医薬用途
JP2015527406A (ja) * 2012-09-11 2015-09-17 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
JP2016525571A (ja) * 2013-07-30 2016-08-25 ドン−ア エスティ カンパニー リミテッド 新規なビフェニル誘導体及びその製造方法
JP2016528199A (ja) * 2013-07-13 2016-09-15 ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド キニン系化合物、その光学異性体及びその製造方法と医薬用途
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
WO2017114377A1 (zh) * 2015-12-29 2017-07-06 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE509931T1 (de) * 2007-03-23 2011-06-15 Abbott Lab Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
KR102239776B1 (ko) * 2016-08-26 2021-04-13 동아에스티 주식회사 (r)-(1-메틸피롤리딘-3-일)메틸(3'-클로로-4'-플루오로-[1,1'-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형
MY200068A (en) * 2016-08-26 2023-12-06 Dong A St Co Ltd Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy
US20200308168A1 (en) 2017-12-04 2020-10-01 Friedrich-Alexander-Universität Erlangen-Nürnberg Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
TW202142236A (zh) 2020-02-03 2021-11-16 美商健臻公司 用於治療與溶體儲積症相關的神經症狀之方法
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63290878A (ja) 1987-04-15 1988-11-28 ビーチャム・グループ・ピーエルシー 新規化合物、その製法及びそれを含む医薬組成物
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
US5834499A (en) 1994-03-11 1998-11-10 Yamanouchi Pharmaceutical Co., Ltd. 5-HT3 receptor agonist, novel thiazole derivative and intermediate thereof
JP2001521033A (ja) 1997-10-29 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌物質としてのプレウロムチリン誘導体
JP2003516391A (ja) * 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリン性レセプターアンタゴニスト活性を有するウレア化合物
JP2004530641A (ja) * 2000-12-22 2004-10-07 アルミラル・プロデスフアルマ・アクチエンゲゼルシヤフト キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1140447A (zh) * 1994-02-10 1997-01-15 山之内制药株式会社 新的氨基甲酸酯衍生物及其药物组合物
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
CZ294251B6 (cs) * 2000-06-27 2004-11-10 Laboratorios S. A. L. V. A. T., S. A. Karbamáty a jejich použití pro výrobu farmaceutického prostředku
IL156558A0 (en) * 2000-12-28 2004-01-04 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
JP2003267977A (ja) * 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
DE10255040A1 (de) 2002-11-26 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbaminsäureester mit anticholinerger Wirksamkeit
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008505118A (ja) 2004-06-30 2008-02-21 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007007282A2 (en) 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
EP2076261A2 (en) 2006-10-03 2009-07-08 Ranbaxy Laboratories, Ltd. Muscarinic receptor antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63290878A (ja) 1987-04-15 1988-11-28 ビーチャム・グループ・ピーエルシー 新規化合物、その製法及びそれを含む医薬組成物
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US5834499A (en) 1994-03-11 1998-11-10 Yamanouchi Pharmaceutical Co., Ltd. 5-HT3 receptor agonist, novel thiazole derivative and intermediate thereof
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
JP2001521033A (ja) 1997-10-29 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌物質としてのプレウロムチリン誘導体
JP2003516391A (ja) * 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリン性レセプターアンタゴニスト活性を有するウレア化合物
JP2004530641A (ja) * 2000-12-22 2004-10-07 アルミラル・プロデスフアルマ・アクチエンゲゼルシヤフト キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Greene's Protective Groups in Organic Synthesis", 2006
AMERICAN JOURNAL RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 158, 1998, pages 154S - 160S
AMERICAN JOURNAL RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 163, 2001, pages 1256 - 1276
JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, 1990, pages 2690 - 2697
JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, 1993, pages 683 - 689
KIM ET AL., SYNLETT., 1999, pages 1239
LIFE SCIENCE, vol. 64, no. 6-7, 1999, pages 449 - 455
LYAKUHIN NO KAIHATSU (DEVELOPMENT OF MEDICINES), vol. 7, 1990, pages 163 - 198
PHARMACOLOGY AND THERAPEUTICS, vol. 58, 1993, pages 319 - 379
PROG. MED., vol. 5, 1985, pages 2157 - 2161
See also references of EP2119716A4
TSUBOI ET AL., BULLETIN OF CHEMICAL SOCIETY OF JAPAN, vol. 60, 1987, pages 2475

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8987453B2 (en) 2006-11-06 2015-03-24 Abbvie Inc. Azaadamantane derivatives and methods of use
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
JP2015527406A (ja) * 2012-09-11 2015-09-17 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
WO2014051055A1 (ja) * 2012-09-28 2014-04-03 東レ株式会社 キヌクリジンウレア誘導体及びその医薬用途
JP2016528199A (ja) * 2013-07-13 2016-09-15 ベイジン エフエスウェルカム テクノロジー ディベロップメント カンパニー リミテッド キニン系化合物、その光学異性体及びその製造方法と医薬用途
JP2016525571A (ja) * 2013-07-30 2016-08-25 ドン−ア エスティ カンパニー リミテッド 新規なビフェニル誘導体及びその製造方法
WO2017114377A1 (zh) * 2015-12-29 2017-07-06 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途

Also Published As

Publication number Publication date
US20100105658A1 (en) 2010-04-29
CN101605784A (zh) 2009-12-16
RU2441868C2 (ru) 2012-02-10
IL200152A0 (en) 2010-04-15
BRPI0806972A2 (pt) 2014-04-08
CN101605784B (zh) 2013-04-10
EP2119716A4 (en) 2011-06-01
JP5293192B2 (ja) 2013-09-18
CA2678193A1 (en) 2008-08-14
KR20090107567A (ko) 2009-10-13
AU2008212171A1 (en) 2008-08-14
JPWO2008096870A1 (ja) 2010-05-27
EP2119716A1 (en) 2009-11-18
MX2009008509A (es) 2009-08-20
RU2009133781A (ru) 2011-03-20
US8367696B2 (en) 2013-02-05

Similar Documents

Publication Publication Date Title
WO2008096870A1 (ja) アザ架橋環化合物
AU2005314155C1 (en) Method for preparing N-phenylpyrazole-1-carboxamides
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
JP2013501720A5 (ja)
MX353957B (es) Carboxamidas heterociclicas fungicidas.
WO2013010946A3 (en) Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests i
WO2007087429A3 (en) Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2008108380A3 (en) Pyrrole compounds
WO2009010660A3 (fr) Indazoles substitues, leur preparation et leur utilisation en therapeutique
TNSN08104A1 (en) Pyrimidine amide compounds as pgds inhibitors
JP2009539848A5 (ja)
WO2007087427A3 (en) Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2012176856A3 (en) 3-arylphenyl sulfide compounds and their use as pesticides
MY148703A (en) Polycyclic cinnamide derivatives
JP2010504286A5 (ja)
EP1798226A4 (en) TRAIZOL DERIVATIVE
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW200628154A (en) Organic compounds
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
WO2008107502A8 (es) Composicion para el tratamiento de enfermedades infecciosas
WO2009017098A1 (ja) トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体
WO2009083608A9 (en) Quinazolines and related heterocyclic compounds, and their therapeutic use
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
JP2016500653A5 (ja)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880004408.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711068

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008557177

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008212171

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200152

Country of ref document: IL

Ref document number: 12009501469

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 4626/CHENP/2009

Country of ref document: IN

Ref document number: 2008711068

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2678193

Country of ref document: CA

Ref document number: MX/A/2009/008509

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008212171

Country of ref document: AU

Date of ref document: 20080208

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097018755

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009133781

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12524758

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0806972

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090807